Imbalances Between Tumor Necrosis Factor-α and Its Soluble Receptor Forms, and Interleukin-1β and Interleukin-1 Receptor Antagonist in BAL Fluid of Cavitary Pulmonary Tuberculosis

This publication has 25 references indexed in Scilit:

• The global tuberculosis situation and the new control strategy of the World Health Organization
  Published by Elsevier ,2004
• Assessment of a Possible Imbalance between Tumor Necrosis Factor (TNF) and Soluble TNF Receptor Forms in Tuberculous Infection of the Central Nervous System
  The Journal of Infectious Diseases, 1995
• Tumor necrosis factor-α is required in the protective immune response against mycobacterium tuberculosis in mice
  Immunity, 1995
• ELEVATED SERUM LEVELS OF INTERLEUKIN‐1 RECEPTOR ANTAGONIST IN POLYMYOSITIS/DERMATOMYOSITIS. A Biologic Marker of Disease Activity with a Possible Role in the Lack of Acute‐Phase Protein Response
  Arthritis & Rheumatism, 1994
• Role of tumor necrosis factor-α in disease states and inflammation
  Critical Care Medicine, 1993
• Two TNF receptors
  Immunology Today, 1992
• Production of interleukin-1-receptor antagonist during experimental endotoxaemia
  The Lancet, 1991
• Infusion of tumor necrosis factor (TNF) causes an increase in circulating TNF-binding protein in humans
  Cytokine, 1990
• The inducing role of tumor necrosis factor in the development of bactericidal granulomas during BCG infection
  Cell, 1989
• A tumor necrosis factor binding protein is present in human biological fluids
  European Journal of Haematology, 1988